E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Chemically Modified Antisense Oligonucleotides: Promising Tools for the Therapy of Diseases"

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (28 February 2017)

Special Issue Editors

Guest Editor
Prof. Dr. Leonidas A. Phylactou

Chief Executive Medical Director, The Cyprus Institute of Neurology & Genetics, PO Box 23462, 1683 Nicosia, Cyprus
Website | E-Mail
Interests: RNA biology; regulatory RNA molecules; muscle regeneration, identification of genetic defects in inherited diseases
Guest Editor
Dr. Nikolas Mastroyiannopoulos

Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology & Genetics, PO Box 23462, 1683 Nicosia, Cyprus
Website | E-Mail
Interests: RNA biology; antisense oligonucleotides; regulatory RNA molecules; muscle regeneration

Special Issue Information

Dear Colleagues,

Antisense oligonucleotides (AONs) have been widely studied as regulators of gene expression by their direct interaction mainly with RNA or RNA regulating molecules. During the last 20 years, AONs have shown to have the potential to treat various diseases, such as cardiovascular diseases, diabetes, cancer, neurological diseases, and muscular dystrophies. Nevertheless, several drawbacks have been identified towards this way. Introduction of chemical modifications to AONs have shown to be beneficial in several cases, providing among other things, resistance to nucleases, stability, and increased target affinity.

I would like to welcome you to submit articles and reviews on chemically modified AONs against diseases.

Prof. Dr. Leonidas A. Phylactou
Dr. Nikolas Mastroyiannopoulos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 850 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • chemical modification
  • antisense oligonucleotide
  • nuclease resistance
  • binding target mRNA
  • systemic delivery
  • tissue delivery

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to Top